SRPT vs. NTRA

Last updated Apr 2, 2026

Compare and contrast key facts about Sarepta Therapeutics, Inc. (SRPT) and Natera, Inc. (NTRA).

Performance

SRPT vs. NTRA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sarepta Therapeutics, Inc. (SRPT) and Natera, Inc. (NTRA). The values are adjusted to include any dividend payments, if applicable.

SRPT vs. NTRA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
SRPT Sarepta Therapeutics, Inc.	2.83%	-82.30%	26.09%	-25.58%	43.90%	-47.18%	32.12%	18.24%	96.14%	102.84%
NTRA Natera, Inc.	-11.30%	44.72%	152.71%	55.94%	-56.99%	-6.16%	195.40%	141.33%	55.28%	-23.23%

Fundamentals

Market Cap SRPT : $2.32B NTRA : $27.78B
EPS SRPT : -$8.11 NTRA : -$1.52
PS Ratio SRPT : 1.05 NTRA : 12.05
PB Ratio SRPT : 2.03 NTRA : 16.22
Total Revenue (TTM) SRPT : $2.20B NTRA : $2.31B
Gross Profit (TTM) SRPT : -$1.05B NTRA : $1.50B
EBITDA (TTM) SRPT : -$778.95M NTRA : -$309.91M

Returns By Period

In the year-to-date period, SRPT achieves a 2.83% return, which is significantly higher than NTRA's -11.30% return. Over the past 10 years, SRPT has underperformed NTRA with an annualized return of 1.03%, while NTRA has yielded a comparatively higher 35.72% annualized return.

SRPT

• 1D: 1.70%
• 1M: 35.60%
• YTD: 2.83%
• 6M: 14.54%
• 1Y: -64.25%
• 3Y*: -45.65%
• 5Y*: -21.91%
• 10Y*: 1.03%

NTRA

• 1D: 1.61%
• 1M: 1.52%
• YTD: -11.30%
• 6M: 25.74%
• 1Y: 44.48%
• 3Y*: 54.11%
• 5Y*: 14.57%
• 10Y*: 35.72%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

SRPT vs. NTRA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SRPT

SRPT Risk / Return Rank: 18
SRPT Sharpe Ratio Rank: 15
SRPT Sortino Ratio Rank: 20
SRPT Omega Ratio Rank: 18
SRPT Calmar Ratio Rank: 12
SRPT Martin Ratio Rank: 23

NTRA

NTRA Risk / Return Rank: 72
NTRA Sharpe Ratio Rank: 75
NTRA Sortino Ratio Rank: 71
NTRA Omega Ratio Rank: 68
NTRA Calmar Ratio Rank: 71
NTRA Martin Ratio Rank: 73

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SRPT vs. NTRA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Sarepta Therapeutics, Inc. (SRPT) and Natera, Inc. (NTRA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	SRPT	NTRA	Difference
Sharpe ratio Return per unit of total volatility	-0.59	1.08	-1.66
Sortino ratio Return per unit of downside risk	-0.42	1.66	-2.07
Omega ratio Gain probability vs. loss probability	0.93	1.21	-0.27
Calmar ratio Return relative to maximum drawdown	-0.80	1.55	-2.35
Martin ratio Return relative to average drawdown	-1.03	4.16	-5.19
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

SRPT vs. NTRA - Sharpe Ratio Comparison

The current SRPT Sharpe Ratio is -0.59, which is lower than the NTRA Sharpe Ratio of 1.08. The chart below compares the historical Sharpe Ratios of SRPT and NTRA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	SRPT	NTRA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.59	1.08	-1.66
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.32	0.26	-0.57
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.01	0.59	-0.57
Sharpe Ratio (All Time) Calculated using the full available price history	-0.02	0.37	-0.39

Correlation

The correlation between SRPT and NTRA is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

SRPT vs. NTRA - Dividend Comparison

Neither SRPT nor NTRA has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

SRPT vs. NTRA - Drawdown Comparison

The maximum SRPT drawdown since its inception was -98.17%, which is greater than NTRA's maximum drawdown of -77.74%. Use the drawdown chart below to compare losses from any high point for SRPT and NTRA.

Drawdown Indicators

	SRPT	NTRA	Difference
Max Drawdown Largest peak-to-trough decline	-98.17%	-77.74%	-20.43%
Max Drawdown (1Y) Largest decline over 1 year	-81.26%	-28.20%	-53.06%
Max Drawdown (5Y) Largest decline over 5 years	-92.72%	-77.74%	-14.98%
Max Drawdown (10Y) Largest decline over 10 years	-93.33%	-77.74%	-15.59%
Current Drawdown Current decline from peak	-87.62%	-20.12%	-67.50%
Average Drawdown Average peak-to-trough decline	-68.02%	-33.71%	-34.31%
Ulcer Index Depth and duration of drawdowns from previous peaks	63.52%	10.51%	+53.01%

Volatility

SRPT vs. NTRA - Volatility Comparison

Sarepta Therapeutics, Inc. (SRPT) has a higher volatility of 34.93% compared to Natera, Inc. (NTRA) at 15.05%. This indicates that SRPT's price experiences larger fluctuations and is considered to be riskier than NTRA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SRPT	NTRA	Difference
Volatility (1M) Calculated over the trailing 1-month period	34.93%	15.05%	+19.88%
Volatility (6M) Calculated over the trailing 6-month period	70.71%	27.84%	+42.87%
Volatility (1Y) Calculated over the trailing 1-year period	109.93%	41.45%	+68.48%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	69.76%	56.95%	+12.81%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	75.46%	61.09%	+14.37%

Financials